Improved glycaemia in type 1 diabetes results in decreased levels of soluble adhesion molecules with no change in serum adiponectin or most acute phase proteins

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 6, 2006, Pages 295-300

  Heliövaara, Maikki K ^a   Teppo, A M ^a   Karonen, S L ^a   Tuominen, J A ^a   Ebeling, P ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

1 acid glycoprotein; Adiponectin; Inflammation; Interleukin 6; Soluble adhesion molecules; Type 1 (insulin dependent) diabetes mellitus

Indexed keywords

ACUTE PHASE PROTEIN; ADIPONECTIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CERULOPLASMIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; OROSOMUCOID; SERUM AMYLOID A; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACUTE-PHASE PROTEINS; ADIPONECTIN; ADULT; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 1; DOWN-REGULATION; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; RESEARCH DESIGN;

EID: 33746671352     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924265     Document Type: Article

References (27)

1. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994; 331: 468-469
2. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987; 294: 1651-1654
3. Breyer JA. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis 1992; 20: 533-547
4. Brownlee M. Glycation and diabetic complications. Diabetes 1994; 43: 836-841
5. Cominacini L, Fratta Pasini A, Garbin U, Campagnola M, Davoli A, Rigoni A, Zenti MG, Pastorino AM, LoCascio V. E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress. Diabetologia 1997; 40: 584-589
6. Cominacini L, Fratta Pasini A, Garbin U, Davoli A, De Santis A, Campagnola M, Rigoni A, Zenti MG, Moghetti P, LoCascio V. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 1995; 38: 1122-1124
7. Cosentino F, Hishikawa K, Katusic ZS, Lüscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96: 25-28
8. Crook MA, Tutt P, Simpsom H, Pickup JC. Serum sialic acid and acute phase proteins in type 1 and type 2 diabetes mellitus. Clin Chim Acta 1993; 219: 131-138
9. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N EnglJ Med 1993; 329: 977-986
10. Ebeling P, Teppo A-M, Koistinen HA, Viikari J, Rönnemaa T, Nissén M, Bergkulla S, Salmela P, Saltevo J, Koivisto VA. Troglitazone reduces hyperglycaemia and selectively acute phase serum proteins in patients with type diabetes. Diabetologia 1999; 42: 1433-1438
11. Elhadd TA, Kennedy G, Hill A, McLaren M, Newton RW, Greene SA, Belch JJ. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no vascular disease. Diab/Metab Res Rew 1999; 15: 405-411
12. Fasching P, Veitl M, Rohac M, Streli C, Schneider B, Waldhausl W, Wagner OF. Elevated concentrations of circulating adhesion molecules and their associations with microvascular complications in insulin-dependent diabetes. J Clin Endocrinol Metab 1996; 81: 4313-4317
13. Honkanen E, Grönhagen-Riska C, Teppo A-M, Maury CPJ, Meri S. Acute-phase proteins during hemodialysis: correlations with serum interleukin-1β levels and different dialysis membranes. Nephron 1991; 57: 283-287
14. Mannucci E, Ognibene A, Cremasco F, Dicembrini I, Bardini G, Brogi M, Terreni A, Caldini A, Messeri G, Rotella CM. Plasma adiponectin and hyperglycaemia in diabetic patients. Clin Chem and Lab Medicine 2003; 41: 1131-1135
15. Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, Paolisso G, Giuliano D. Circulating adhesion molecules in humans: role of hyperglycaemia and hyperinsulinemia. Circulation 2000; 101: 2247-2251
16. McMillan DE. Increased levels of acute-phase serum proteins in diabetes. Metabolism 1989; 38: 1042-1046
17. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990a; 39: 1116-1124
18. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Ellis D, LaPorte RE, Kuller LH, Wolfson SK Jr, Drash AL. Factors associated with avoidance of severe complications after 26 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study 1. Diabetes Care 1990b; 13: 741-747
19. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S. Novel modulator for endothelial adhesion molecules. Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476
20. Parving H-H, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, Laurizen M, Hougaard P, Laurizen E. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ 1988; 296: 156-160
21. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292
22. Raitakari OT, Celermajer DS. Testing for endothelial dysfunction. Ann Med 2000; 32: 293-304
23. Schaffler A, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J, Zietz B. Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2. Exp Clin Endocrinol Diabetes 2004; 112: 383-389
24. Schalkwijk CG, Poland DCW, van Dijk W, Kok A, Emeis JJ, Dräger AM, Doni A, van Hinsbergh VW, Stehouwer CD. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351-357
25. The EURODIAB IDDM Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 1994; 37: 278-285
26. Yudkin JS, Panahloo A, Stehouwer C, Emeis JJ, Bulmer K, Mohammed-Ali V, Denver AE. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 2000; 43: 1099-1106
27. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscl Thromb Vasc Biol 1999; 19: 972-978